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Abstract:
Introduction: A critical surgical goal for oral cancer is achieving negative resection margins with no residual
malignant cells, to prevent disease recurrence. The quantitative Malignancy Index Diagnostic System
(qMIDS) is the first FOXM1 oncogene-based diagnostic test developed for quantifying oral squamous cell
carcinoma. This highly sensitive technique converts gene expression into a digital index to quantify cancer
risk.
 
Methods: qMIDS compares total expression of 16 genes with median normal gene expression levels. Real-
time absolute quantitative PCR is used for mRNA transcript quantification. By conversion of gene levels via
the qMIDS algorithm into a metric ‘malignancy index’ score, risk of a given biopsy sample becoming
cancerous can be quantified. This project aimed to validate a faster version of the qMIDS protocol, taking less
than 90 minutes to obtain diagnostic results.
 
Results: Testing OSCC patient biopsies from normal margin and tumour cores, results demonstrate a high
detection rate (>90%) and low false positive rate (<3%), indicating good test performance at a qMIDS cut-off
of 4.0. qMIDS is capable of segregating the malignancy status of OSCC clinical tissue biopsies with a high
degree of confidence (p<0.001). Molecular tissue topology can also be reconstructed using qMIDS on
surgical samples for margin assessment and determination of tumour heterogeneity.
 
Conclusion: The qMIDS assay robustly measures a FOXM1-driven oncogenic program in OSCC to quantify
malignancy. Benefits include its objectivity as a reproducible, diagnostic method to quantitatively measure the
malignancy of a biopsy tissue sample based on digital molecular profile in HNSCC diagnosis and tumour
margin analysis. 
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